By Bizodisha Bureau, Bhubaneswar, December 15, 2025: The state will host the Pharma Conclave 2025 on Tuesday here, bringing together policymakers, global investors, pharma leaders, and medical technology innovators To further catalyse industry engagement the conclave is expected to play a key role in converting investment proposals into firm commitments.

Earlier in a major strategic move, the state government had launched a comprehensive Pharma–Medical Devices Policy designed to position the state as a prominent hub for pharmaceutical and medical technology manufacturing. The policy introduces a suite of high-value incentives aimed at attracting large-scale investments into a sector that officials admit has historically had a “limited presence” in the state.

Under the new policy framework, investors will receive a 30% capital investment subsidy on plant and machinery, 100% stamp duty exemption on concessional industrial land, and a power subsidy of Rs 2 per unit alongside complete reimbursement of electricity duty. The policy also provides wage incentives for five years—Rs 15,000 per month for women and Rs 12,500 per month for men—along with ESI and EPF reimbursement, making Odisha one of India’s most competitive destinations for life-sciences manufacturing.

To streamline implementation and provide end-to-end investor facilitation, the government has established the Odisha Pharmaceutical Development Cell (OPDC). The cell will coordinate policy rollout, accelerate approvals, and shape a structured ecosystem for pharma and med-tech enterprises. The state is also progressing toward the creation of sector-specific Spoeiucal conomic Zone (SEZ)s and additional infrastructure dedicated to the life sciences industry.

The impact of these reforms is already becoming visible. According to state authorities, nine pharmaceutical and biotechnology companies have submitted investment intents worth Rs 4,349 crore to set up manufacturing units, biotech plants, and healthcare facilities across Odisha. These developments align with the state’s broader Viksit Odisha 2036 vision, which aims to build a future-ready, innovation-driven industrial economy.

With investment promotion activities led by IPICOL (Industrial Promotion & Investment Corporation of Odisha Ltd.), the government has intensified outreach to industry players, highlighting streamlined processes, robust infrastructure support, and the compelling incentive package under the new policy.

As Odisha accelerates its transition from a limited pharma presence to a high-potential life-sciences destination, the new policy marks a pivotal step in strengthening the state’s standing as an emerging pharma-med-tech hub in India’s rapidly evolving healthcare manufacturing landscape.